Immuno-metabolic depression & the future of precision psychiatry — Brenda Penninx (Amsterdam UMC)
The Mental ElfShow Notes
Depression is not one thing, and treating it as if it were may be why so many people don't get better. In this episode, Prof Brenda Penninx offers a sharper way to think about it.
Recorded ahead of her guest lecture at the British Association for Psychopharmacology (BAP) Summer Meeting, Brenda talks to André Tomlin (The Mental Elf) about "immuno-metabolic depression": the 20–30% of depressed patients who show low-grade inflammation and metabolic dysregulation, clustered with atypical, energy-related symptoms such as fatigue, oversleeping, increased appetite and leaden paralysis. Drawing on the large Netherlands Study of Depression and Anxiety (NESDA), she explains why these patients respond slightly less well to standard antidepressants, and why that matters.
00:00 Meet Brenda Penninx 01:03 Why Depression Varies 03:03 Defining Immunometabolic Depression 04:11 Cause or Vicious Cycle 05:56 Treatment Targets and Trials 07:41 Proof of Concept IL6 Study 10:26 Lifestyle as Medicine 13:19 From Concept to Clinic 15:11 Mind Body Care Gap 16:29 Conference Takeaways
Is the biology a cause or a consequence of depression? Neither, Brenda argues: it's a vicious cycle, with common roots in genetics, lifestyle and childhood adversity. She discusses what this means for treatment (anti-inflammatory drugs, metabolic and lifestyle interventions) and why the key is targeting the right subgroup rather than the whole depressed population. She reflects on the recent Bristol tocilizumab proof-of-concept trial (Foley & Khandaker, JAMA Psychiatry), the Wellcome-funded ASPIRE project bringing these trials together, and why running therapy should be treated as a genuine, supported intervention rather than a slogan.
Finally, the conversation turns to what still stands between concept and clinic (how to identify the right patients, which intervention to choose) and Brenda's wish to bring mental and physical healthcare back together.
About the guest: Prof Brenda Penninx is Professor of Psychiatric Epidemiology at Amsterdam UMC / Vrije Universiteit Amsterdam and lead of the Netherlands Study of Depression and Anxiety (NESDA).
Find out more about Brenda Penninx's talk at the 2026 BAP Summer Meeting: https://www.bap.org.uk/summersessiondetails.php?meetingID=19&sessionID=740 Hosted on Acast. See acast.com/privacy for more information.
More from The Mental Elf
Professor Eileen Joyce and Professor Trevor Robbins, two of her closest colleagues and former PhD students, join André Tomlin to remember Professor Susan (Sue) Iversen (1940–2025), the scientist who fused psychopharmacology and neuropsychology and helped found the field of neuropsychopharmacology.
Catherine Harmer, Professor of Cognitive Neuroscience at Oxford and outgoing president of the British Association of Psychopharmacology (BAP), and Naomi Fineberg, Professor of Psychiatry at the University of Hertfordshire and incoming BAP president, discuss how BAP brings together non-clinical scientists, experimental medicine researchers, clinicians, and industry to translate discoveries into patient care.
Oxford psychologist Dr Lucy Foulkes discusses myths and research around adolescent mental health ahead of her public lecture at the British Association of Psychopharmacology Conference (Sunday, 19 July).
Five years of research. 14,000 students surveyed. Interventions tested. A whole-university framework developed. Now: what needs to change?
The Nurture-U Compassionate Campus framework identifies three pillars: culture, communication, and community. What does that mean in practice? How do mitigating circumstances systems end up failing the students who need them most? And is it really as simple as putting benches inside buildings?